<DOC>
	<DOCNO>NCT02057237</DOCNO>
	<brief_summary>1 . The primary objective study assess feasibility treat patient metastatic castration resistant prostate cancer mitotane . Secondary objective assess safety tolerability well response rate therapy 2 . To assess toxicity Mitotane men HRPC 3 . To assess relationship baseline serum adrenal androgen response Mitotane</brief_summary>
	<brief_title>A Safety Feasibility Study Mitotane Prostate Cancer</brief_title>
	<detailed_description>All patient undergo pre-study assessment symptom , performance status , ECG , CT abdomen/pelvis , Bone scan , Complete blood count test ( hematology ) , Biochemistry test like serum electrolyte , liver function test , coagulation profile , testosterone PSA test . Mitotane administer 1.5g daily escalation maximum 5 g daily adjust accord serum level tolerability Physical examination , hematology , biochemistry test , toxicity evaluation measure throughout patient protocol treatment Mitotane serum level analyze every second cycle Research blood include ; ACTH , cortisol , deoxycorticosterone , aldosterone , corticosterone , testosterone , androstenedione , dehydroepiandrostenedione ( DHEA ) , DHEA sulfate ( DHEA-S ) estradiol collect cycle 1,3 5</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Mitotane</mesh_term>
	<criteria>Biopsyproven prostate cancer OR clinical picture consistent metastatic prostate cancer high level serum PSA ( &gt; 20ng/ml ) Progressed docetaxel chemotherapy minimum 3 cycle and/or stop treatment toxicity . Patients may previous mitoxantrone , either docetaxel treatment Response minimum 50 % fall PSA maintain 4 week progress abiraterone treatment At least 2 consecutive rise PSAs measure least 1 week apart . Patients must cease abiraterone least 1 week prior . Serum PSA &gt; 10 ng/ml ECOG performance status &lt; /= 1 ( Karnofsky &gt; /=60 % ) Normal organ marrow function define : Absolute neutrophils count ≥ 1,500/uL platelet ≥100,000/uL total bilirubin ≤1.5 X institutional ULN AST ( SGOT ) /ALT ( SGPT ) ≤ 2 X institutional ULN creatinine ≤ 1.5 X institutional ULN Men must agree use adequate contraception prior study entry Life expectancy &gt; 3 month CRPC document PSA increase despite : ) orchidectomy OR b ) continuous LHRH agonist treatment . This documented baseline serum testosterone suppression ( &lt; 1.75 nmol/L ) Prior anticancer treatment Mitotane May receive investigational anticancer agent study Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure evidence cardiac dysfunction , unstable angina pectoris , cardiac arrhythmia , active peptic ulcer disease , poorly control diabetes mellitus , clinically significant untreated ophthalmologic ( e.g . Sjogrens etc . ) gastrointestinal condition ( e.g . Crohns disease , ulcerative colitis ) psychiatric illness/social situation would limit compliance study requirement Active malignancy site exclude squamous cell basal cell carcinoma skin Radiotherapy within past 4 week Preexisting pituitary adrenal dysfunction Patients spironolactone may interfere action mitotane Patients warfarin mitotane may unpredictably interfere INR measurement</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>